Form D · Biotechnology
Aravive Biologics, Inc.
Houston, TX · CIK 0001710436
Offering snapshot reported Jul 25, 2017 · SEC filing
- Reported sold
- $363K Offering amount: $363K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $363K Reported outside-investor minimum
- First sale
- Jul 14, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 25, 2017 | Initial | $363,311 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-291420
Does not include securities sold under Regulation S
Source: Form D, filed Jul 25, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Stephen Eck | Director, Executive |
| Amato Giaccia | Director, Executive |
| Karen Liu | Director |
| Vinay Shah | Executive |
| Ray Tabibiazar | Director, Executive |
| Xin Eric Zhang | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Lyondellbasell Tower 1221 Mckinney Street, Ste. 3200
Houston, TX, 77010
Houston, TX, 77010